Short Interest in Dermata Therapeutics, Inc. (NASDAQ:DRMA) Increases By 112.9%

Dermata Therapeutics, Inc. (NASDAQ:DRMA) was the target of a large increase in short interest in January. As of January 31st, there was short interest totalling 294,200 shares, an increase of 112.9% from the January 15th total of 138,200 shares. Currently, 47.5% of the shares of the company are sold short. Based on an average daily volume of 460,200 shares, the short-interest ratio is presently 0.6 days.

Dermata Therapeutics Stock Performance

NASDAQ DRMA traded down $0.02 during mid-day trading on Thursday, reaching $1.13. 97,433 shares of the stock were exchanged, compared to its average volume of 509,184. Dermata Therapeutics has a 1 year low of $1.00 and a 1 year high of $7.62. The business’s 50 day moving average is $1.25 and its 200-day moving average is $1.48. The company has a market capitalization of $2.31 million, a P/E ratio of -0.07 and a beta of 0.67.

Dermata Therapeutics Company Profile

Dermata Therapeutics, Inc, a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.